| Q34611616 | An overview of small-molecule inhibitors of VEGFR signaling |
| Q36626892 | Angiogenesis in melanoma |
| Q37261502 | Biological functions of the low and high molecular weight protein isoforms of fibroblast growth factor-2 in cardiovascular development and disease |
| Q37991379 | ENMD-2076 for hematological malignancies |
| Q37771144 | Hepatic drug-metabolizing enzyme induction and implications for preclinical and clinical risk assessment |
| Q35945084 | Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesis |
| Q38057769 | Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011). |
| Q37052713 | Liver regeneration and tumor stimulation--a review of cytokine and angiogenic factors. |
| Q38796360 | Multi-kinase inhibitors, AURKs and cancer |
| Q36585602 | New target-based agents involve new clinical trial designs. |
| Q37351958 | SU6668 suppresses proliferation of triple negative breast cancer cells through down-regulating MTDH expression |
| Q38764789 | Synthesis and Cytotoxic Activity of Biphenylurea Derivatives Containing Indolin-2-one Moieties. |
| Q37362620 | Therapeutic perspectives in bronchial vascular remodeling in COPD. |